Synthesis method of novel beta-lactamase inhibitor intermediate

By optimizing the reaction conditions and steps, the synthesis route of β-lactamase inhibitor intermediates is simplified, the problem of low product yield caused by TBS shedding is solved, and the preparation of a highly efficient new β-lactamase inhibitor intermediate is achieved. .

CN118930575APending Publication Date: 2024-11-12HEYA PHARM TECH (WUHAN) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410981456.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the existing synthesis method of β-lactamase inhibitor intermediates, TBS functional groups are prone to fall off, resulting in low product yield and cumbersome reaction steps.

Method used

Under gas protection conditions, a multi-step reaction is carried out: compound methyl is mixed with ethyl acetate and then added dropwise to hydrochloric acid-ethyl acetate solution, followed by reaction with imidazole and tert-butyldimethylsilyl trifluoromethanesulfonate, and then with The reaction of diisopropylethylamine and triphosgene is obtained by optimizing the reaction conditions and steps to obtain the new β-lactamase inhibitor intermediate (2S,5R)-6-(tert-butyldimethylsilyloxy)- 4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-formamide.

Benefits of technology

The synthesis route is simplified, the product yield is improved, and the problem of TBS fall off is avoided. The operation is relatively simple and the product purification effect is significant.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930575A_ABST
    Figure CN118930575A_ABST
Patent Text Reader

Abstract

The invention provides a novel beta-lactamase inhibitor intermediate synthesis method, which comprises: S1, mixing a compound A with ethyl acetate under a gas protection condition, dropwise adding a hydrochloric acid-ethyl acetate solution under an ice bath condition, and carrying out a reaction at a room temperature to obtain a compound B; s2, under the condition of gas protection, adding the compound B in the step S1, imidazole, DMF (Dimethyl Formamide) and DCM (Dimethyl Formamide) as solvents, then dropwise adding tert-butyldimethylsilyl trifluoromethanesulfonate under the condition of ice bath, and reacting at the temperature of 0-5 DEG C to obtain a compound C; s3, under the condition of gas protection, adding the compound C in the step S2, DCM and diisopropylethylamine, then dropwise adding triphosgene and DCM as solvents under the condition of ice bath, reacting at room temperature, and pouring into water for quenching to obtain the novel beta-lactamase inhibitor intermediate; compared with the existing synthesis method, the synthesis method disclosed by the invention has the advantages of simple steps, capability of effectively avoiding TBS removal and better yield.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of organic synthesis, and in particular to a method for synthesizing a novel beta-lactamase inhibitor intermediate. Background Art

[0002] β-lactamase inhibitors are an important class of drugs for the treatment of bacterial infections. They can inactivate antibiotics by decomposing the β-lactam nucleus and inhibit the production of β-lactamase or reduce its activity, thereby effectively solving the problem of bacterial resistance.

[0003] The existing DBO-type β-lactamase inhibitors are prepared by continuous flow microchannel technology, and the yield of the target product can reach 95% ("Microchannel Technology Synthesis of Key Intermediates of β-lactamase Inhibitors" Zhao Chenxi, 2024, Vol. 46, No. 1, 7-11). However, the technology is not yet fully mature and the conditions are relatively harsh.

[0004] In addition, there are also foreign literature reports that the synthesis method of ETX0282 requires more than a dozen steps of reaction, and the reaction process is cumbersome. In the process of synthesizing ETX0282, the TBS functional group is easily removed, which greatly affects the yield of the final product.

[0005] In view of this, the existing synthesis methods of novel β-lactamase inhibitor intermediates need to be further improved. Summary of the invention

[0006] In view of this, the present invention proposes a novel method for synthesizing a β-lactamase inhibitor intermediate, which solves the problem of low yield caused by easy shedding of TBS during the synthesis of the β-lactamase inhibitor intermediate in the prior art.

[0007] The technical solution of the present invention is achieved in this way:

[0008] The present invention provides a method for synthesizing a novel β-lactamase inhibitor intermediate, comprising the following steps:

[0009] S1. Under gas protection conditions, compound A is mixed with ethyl acetate, and then hydrochloric acid-ethyl acetate solution is added dropwise at -5-0°C, and the reaction is carried out at 20-25°C. After the reaction is completed, the reaction solution is filtered out, and the remaining solid is washed with ethyl acetate to obtain compound B;

[0010] S2. Under gas protection conditions, add the compound B and imidazole described in step S1, use DMF and DCM as solvents, then dropwise add tert-butyldimethylsilyl trifluoromethanesulfonate at -5-0°C, react at 0-5°C, monitor the reaction by TLC, quench, extract the organic phase, dry, and purify to obtain compound C;

[0011] S3, under gas protection conditions, add compound C described in step S2, DCM and diisopropylethylamine, then add triphosgene dropwise at -5-0°C, use DCM as solvent, react at 20-25°C, monitor the reaction by TLC, pour into water to quench, combine the aqueous phase and the organic phase, dry and purify to obtain the novel β-lactamase inhibitor intermediate;

[0012] The novel β-lactamase inhibitor intermediate is It is called (2S,5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide.

[0013] On the basis of this technical solution, preferably, the compound A is

[0014] On the basis of this technical solution, preferably, the molar ratio of compound A to hydrochloric acid in step S1 is 1:3-8.

[0015] On the basis of this technical solution, preferably, the concentration of hydrochloric acid in the hydrochloric acid-ethyl acetate solution is 1-5M.

[0016] On the basis of this technical solution, preferably, the volume ratio of the hydrochloric acid-ethyl acetate solution to the ethyl acetate is 3-10:1.

[0017] On the basis of this technical solution, preferably, the equivalent ratio of the compound 2, imidazole and tert-butyldimethylsilyl trifluoromethanesulfonate described in step S2 is 1:3-6:1-3.

[0018] On the basis of this technical solution, preferably, the equivalent ratio of the compounds propane, diisopropylethylamine and triphosgene in step S3 is 1:3-5:0.3-0.4.

[0019] On the basis of this technical solution, preferably, in the TLC monitoring reaction described in step S2, the TLC eluent is DCM and methanol, and the volume ratio of DCM to methanol is 15-20:1.

[0020] On the basis of this technical solution, preferably, in step S3, the reaction is monitored by TLC, and the TLC eluent is petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 0.5-2:1.

[0021] On the basis of this technical solution, preferably, the quenching method in step S2 is to pour the reaction into a sodium bicarbonate solution, separate the liquids, wash with saturated brine, extract the organic phase, and dry it.

[0022] On the basis of this technical solution, preferably, the mass concentration of the sodium bicarbonate solution is 10-15%.

[0023] The synthesis method of the novel β-lactamase inhibitor intermediate of the present invention has the following beneficial effects compared with the prior art:

[0024] The existing ETX0282 intermediate (2S, 5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide has a complicated synthesis method, the TBS functional group is easily removed, and the operation is relatively inconvenient; the present application designs a new synthesis route with simple steps, easy operation and high yield. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0026] Figure 1 is the hydrogen NMR spectrum of compound B in step S1 of the synthesis method of the present invention;

[0027] Figure 2 is the hydrogen NMR spectrum of compound C in step S2 of the synthesis method of the present invention;

[0028] Figure 3 The hydrogen nuclear magnetic spectrum of the novel β-lactamase inhibitor intermediate (2S, 5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide of the present invention;

[0029] Figure 4 The schematic diagram is a synthetic method of the novel β-lactamase inhibitor intermediate of the present invention. DETAILED DESCRIPTION

[0030] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] Example 1

[0032] A method for synthesizing a novel β-lactamase inhibitor intermediate comprises the following steps:

[0033] S1. Under nitrogen protection, compound A is mixed with ethyl acetate. The compound A is The feeding amount is 0.169 mol, the molar ratio of the compound A to hydrochloric acid is 1:3, and then hydrochloric acid-ethyl acetate solution is added dropwise at -5°C, the concentration of hydrochloric acid in the hydrochloric acid-ethyl acetate solution is 5M, and the volume ratio of the hydrochloric acid-ethyl acetate solution to the ethyl acetate is 3:1; react at 20°C, monitor the reaction after completion, filter out the reaction solution, and wash the remaining solid with 50mL of ethyl acetate to obtain compound B; the synthesis method of compound A can refer to the existing literature report ("Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases" J. Med. Chem. 2020, 63, 12511-12525).

[0034]

[0035] S2. Under nitrogen protection, add the compound B and imidazole described in step S1, 200mL DMF and 800mL DCM as solvents, and then dropwise add tert-butyldimethylsilyl trifluoromethanesulfonate at -5°C, wherein the equivalent ratio of the compound B, imidazole and tert-butyldimethylsilyl trifluoromethanesulfonate is 1:3:1, react at 0°C, monitor the reaction by TLC, quench, extract the organic phase, dry and purify to obtain compound C, the reaction is monitored by TLC, the TLC eluent is DCM and methanol, and the volume ratio of DCM to methanol is 15:1; wherein the quenching method is to pour the reaction into 1L sodium bicarbonate solution with a mass concentration of 10%, separate the liquids, wash with saturated brine, extract the organic phase, and dry;

[0036]

[0037] S3, under nitrogen protection, add compound C, DCM and diisopropylethylamine described in step S2, then add triphosgene dropwise at -5°C, 600mL DCM as solvent, wherein the equivalent ratio of compound C, diisopropylethylamine and triphosgene is 1:3:0.3, react at 20°C, after TLC monitoring the reaction is complete, pour into 200mL water for quenching, combine the aqueous phase and the organic phase, dry and purify to obtain the novel β-lactamase inhibitor intermediate; the TLC monitoring reaction, the TLC eluent is petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 0.5:1;

[0038]

[0039] Specifically, the novel β-lactamase inhibitor intermediate is It is called (2S,5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide.

[0040] As a result, the (2S,5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide obtained in this example was a light yellow solid. After LCMS detection, the LCMS result was: 312.15 [M+H] + The total yield of the three steps is 47.5%

[0041] Example 2

[0042] A method for synthesizing a novel β-lactamase inhibitor intermediate comprises the following steps:

[0043] S1. Under gas protection conditions, compound A is mixed with ethyl acetate, wherein compound A is The feed amount is 0.169 mol, and then a hydrochloric acid-ethyl acetate solution is added dropwise at 0°C, the molar ratio of the compound A described in step S1 to the hydrochloric acid is 1:8, the concentration of the hydrochloric acid in the hydrochloric acid-ethyl acetate solution is 3M, and the volume ratio of the hydrochloric acid-ethyl acetate solution to the ethyl acetate is 10:1, and the reaction is carried out at 25°C. After monitoring the reaction is complete, the reaction solution is filtered off, and the remaining solid is washed with 50 mL of ethyl acetate to obtain compound B;

[0044] The compound B is a purple solid, and its hydrogen spectrum is as follows Figure 1 As shown, its hydrogen spectrum nuclear magnetic data is:

[0045] 1 H NMR (400MHz, DMSO-d6) δ8.14(s,1H),7.76(s,1H),5.97(d,J=4.0Hz,1H),4.55(s,1H),4.11(s,1H),3.57(d,J=4.0Hz,1H),1.89(s,3H).

[0046] S2. Under gas protection conditions, add the compound B and imidazole described in step S1, 300 mL of DMF and 900 mL of DCM as solvents, and then dropwise add tert-butyldimethylsilyl trifluoromethanesulfonate at 0°C, wherein the equivalent ratio of the compound B, imidazole and tert-butyldimethylsilyl trifluoromethanesulfonate is 1:6:3, react at 5°C, and monitor the reaction by TLC after the reaction is complete. The TLC eluent is DCM and methanol, and the volume ratio of DCM to methanol is 20:1, and quench. The quenching method is to pour the reaction into 1.2 L of sodium bicarbonate solution, the mass concentration of the sodium bicarbonate solution is 15%, separate the liquids, wash with saturated brine, extract the organic phase, dry, and purify to obtain compound C;

[0047] Specifically, compound C is a light yellow solid, and its hydrogen spectrum is as follows: Figure 2 As shown, its hydrogen spectrum nuclear magnetic data is:

[0048] 1 H NMR (400MHz, DMSO-d6) δ7.35(s,1H),7.06(s,1H),6.01(d,J=8.0Hz,1H),5.75(s,1H)3.53(s,1H),3.05(d,J=8.0Hz,1H H), 2.75 (d, J = 8.0Hz, 1H), 2.53 (s, 1H), 2.48 (s, 1H), 1.72 (s, 3H), 0.86 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H).

[0049] S3. Under gas protection conditions, add compound C, DCM and diisopropylethylamine described in step S2, and then add triphosgene dropwise at 0°C. The equivalent ratio of compound C, diisopropylethylamine and triphosgene described in step S3 is 1:5:0.4. 750 mL of DCM is used as solvent. The reaction is carried out at 25°C. The reaction is monitored by TLC to be complete. The TLC monitoring reaction is performed. The TLC eluent is petroleum ether and ethyl acetate, and the volume ratio of petroleum ether and ethyl acetate is 2:1. Pour into 300 mL of water for quenching, combine the aqueous phase and the organic phase, dry and purify to obtain the novel β-lactamase inhibitor intermediate.

[0050] The novel β-lactamase inhibitor intermediate is a light yellow foamy solid. It is called (2S,5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide, and its hydrogen spectrum is as follows Figure 3 As shown, its hydrogen spectrum nuclear magnetic data is:

[0051] 1H NMR (400MHz, DMSO-d6) δ7.51(s,1H),7.32(s,1H),5.47(d,J=4.0Hz,1H),4.12(s,d,J=4.0H z,1H),3.57(s,1H),3.20-3.15(m,2H),1.78(s,3H),0.90(s,9H),0.14(s,3H),0.12(s,3H).

[0052] As a result, the (2S,5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide obtained in this example was a light yellow solid, and the total yield of three steps was 40.8%.

[0053] Example 3

[0054] A novel method for synthesizing a novel β-lactamase inhibitor intermediate, such as Figure 4 As shown, the following steps are included:

[0055] S1. Under gas protection conditions, compound A is mixed with ethyl acetate, wherein compound A is The feed amount is 0.169 mol, the molar ratio of the compound A to hydrochloric acid is 1:5, then a hydrochloric acid-ethyl acetate solution is added dropwise at 0°C, the concentration of hydrochloric acid in the hydrochloric acid-ethyl acetate solution is 3M, the volume ratio of the hydrochloric acid-ethyl acetate solution to the ethyl acetate is 7:1, and the reaction is carried out at 22°C. After monitoring the reaction is complete, the reaction solution is filtered off, and the remaining solid is washed with 50 mL of ethyl acetate to obtain compound B;

[0056] S2. Under gas protection conditions, add the compound B and imidazole described in step S1, 250 mL of DMF and 850 mL of DCM as solvents, and then dropwise add tert-butyldimethylsilyl trifluoromethanesulfonate at 0°C, wherein the equivalent ratio of the compound B, imidazole and tert-butyldimethylsilyl trifluoromethanesulfonate is 1:5.5:2.5, react at 2°C, and the reaction is complete by TLC monitoring, wherein the TLC monitoring reaction, the TLC eluent is DCM and methanol, and the volume ratio of DCM to methanol is 18:1, quench, and the quenching method is to pour the reaction into 1.1 L of sodium bicarbonate solution, the mass concentration of the sodium bicarbonate solution is 12%, separate the liquids, wash with saturated brine, extract the organic phase, dry, and purify to obtain compound C;

[0057] S3. Under gas protection conditions, add compound C, DCM and diisopropylethylamine described in step S2, and then add triphosgene dropwise at 0°C. The equivalent ratio of compound C, diisopropylethylamine and triphosgene described in step S3 is 1:4.5:0.35. 700 mL of DCM is used as solvent. The reaction is carried out at 22°C. After the reaction is completed, the reaction is monitored by TLC. The TLC eluent is petroleum ether and ethyl acetate, and the volume ratio of petroleum ether and ethyl acetate is 1:1. Pour into 250 mL of water for quenching, combine the aqueous phase and the organic phase, dry and purify to obtain the novel β-lactamase inhibitor intermediate.

[0058] Specifically, the novel β-lactamase inhibitor intermediate is It is called (2S,5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide.

[0059] As a result, the (2S,5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide obtained in this example was a light yellow solid, and the total yield of three steps was 43.5%.

[0060] Example 4

[0061] A novel method for synthesizing a novel β-lactamase inhibitor intermediate, such as Figure 4 As shown, the following steps are included:

[0062] S1. Under gas protection conditions, compound A is mixed with ethyl acetate, wherein compound A is The feed amount is 0.150 mol, the molar ratio of the compound A to hydrochloric acid is 1:6, the concentration of hydrochloric acid in the hydrochloric acid-ethyl acetate solution is 1 M, and the volume ratio of the hydrochloric acid-ethyl acetate solution to the ethyl acetate is 8.5:1, then the hydrochloric acid-ethyl acetate solution is added dropwise at 0°C, reacted at 22°C, and after monitoring the reaction completion, the reaction solution is filtered off, and the remaining solid is washed with 40 mL of ethyl acetate to obtain compound B;

[0063] S2. Under gas protection conditions, add the compound B and imidazole described in step S1, 150 mL of DMF and 600 mL of DCM as solvents, then dropwise add tert-butyldimethylsilyl trifluoromethanesulfonate at 0°C, the equivalent ratio of the compound B, imidazole and tert-butyldimethylsilyl trifluoromethanesulfonate is 1:5.5:2.5, react at 2°C, and the reaction is complete by TLC monitoring, wherein the TLC monitoring reaction, the TLC eluent is DCM and methanol, and the volume ratio of DCM to methanol is 18:1, quench, the quenching method is, pour the reaction into 800 mL of sodium bicarbonate solution, the mass concentration of the sodium bicarbonate solution is 12%, separate the liquids, wash with saturated brine, extract the organic phase, dry and purify to obtain compound C;

[0064] S3. Under gas protection conditions, add compound C, DCM and diisopropylethylamine described in step S2, and then add triphosgene dropwise at 0°C. The equivalent ratio of compound C, diisopropylethylamine and triphosgene described in step S3 is 1:4.5:0.35. 600 mL of DCM is used as solvent. The reaction is carried out at 22°C. After the reaction is completed, the reaction is monitored by TLC. The TLC eluent is petroleum ether and ethyl acetate, and the volume ratio of petroleum ether and ethyl acetate is 1:1. Pour into 150 mL of water for quenching, combine the aqueous phase and the organic phase, dry and purify to obtain the novel β-lactamase inhibitor intermediate.

[0065] Specifically, the novel β-lactamase inhibitor intermediate is It is called (2S,5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide.

[0066] As a result, the (2S,5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide obtained in this example was a light yellow solid, and the total yield of three steps was 42.6%.

[0067] Comparative Example 1

[0068] A novel method for synthesizing a novel β-lactamase inhibitor intermediate, wherein the β-lactamase inhibitor intermediate is (2S, 5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide, which is a light yellow solid. The feed amount is 0.169 mol.

[0069] The synthesis method refers to the synthesis process of compounds 34 to 36 in (Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases, J. Med. Chem. 2020, 63, 12511-12525).

[0070] As a result, the total yield of the three steps of compound 36 synthesized in this example was 25%, which was significantly lower than that in Example 1.

[0071] Comparative Example 2

[0072] A novel method for synthesizing a novel β-lactamase inhibitor intermediate, wherein the β-lactamase inhibitor intermediate is (2S, 5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide, which is a light yellow solid. The feed amount is 0.169 mol.

[0073] The difference from Example 1 is that the molar ratio of compound A to hydrochloric acid in step S1 is 1:1.

[0074] As a result, the yield of the β-lactamase inhibitor intermediate synthesized in this example was 30.5%.

[0075] Comparative Example 3

[0076] A novel method for synthesizing a novel β-lactamase inhibitor intermediate, wherein the β-lactamase inhibitor intermediate is (2S, 5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide, which is a light yellow solid. The feed amount is 0.169 mol.

[0077] The difference from Example 1 is that the equivalent ratio of the compound 2, imidazole and tert-butyldimethylsilyl trifluoromethanesulfonate in step S2 is 1:2:1.

[0078] As a result, the yield of the β-lactamase inhibitor intermediate synthesized in this example was 22.7%.

[0079] Comparative Example 4

[0080] A novel method for synthesizing a novel β-lactamase inhibitor intermediate, wherein the β-lactamase inhibitor intermediate is (2S, 5R)-6-(tert-butyldimethylsilyloxy)-4-methyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-3-ene-2-carboxamide, which is a light yellow solid. The feed amount is 0.169 mol.

[0081] The difference from Example 1 is that the equivalent ratio of the compound propane, diisopropylethylamine and triphosgene in step S3 is 1:1.5:0.05.

[0082] As a result, the target product was not obtained in this example, which may be due to the small amount of nucleophilic reagents diisopropylethylamine and triphosgene added.

[0083] As can be seen from the above, the comparison between Example 1 and Comparative Example 1 shows that compared with the prior art, the method step design of the present invention is more reasonable, mainly avoiding the step of removing Boc with ZnBr2 in the comparative example, which requires very strict anhydrous operation and has a low yield. The method of first removing Boc and then selectively adding TBS protecting group in this Example 1 is more reasonable and has a higher yield.

[0084] Comparison between Example 1 and Comparative Examples 2-4 shows that when the equivalent of tert-butyldimethylsilyl trifluoromethanesulfonate is greater than 2 equivalents, tert-butyldimethylsilyl protection can be better obtained at the oxygen position, thereby improving the yield. At the same time, the problem of easy shedding of TBS is solved by the order of deprotection.

[0085] The invention provides a novel method for synthesizing a β-lactamase inhibitor intermediate, which can effectively avoid the technical problem of TBS shedding in the prior art, has simple steps and high yield.

[0086] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for synthesizing a novel β-lactamase inhibitor intermediate. It is characterized in that The steps include: S1. Under gas protection conditions, compound A is mixed with ethyl acetate, and then hydrochloric acid-ethyl acetate solution is added dropwise at -5-0°C, and the reaction is carried out at 20-25°C. After the reaction is completed, the reaction solution is filtered out, and the remaining solid is washed with ethyl acetate to obtain compound B; S2. Under gas protection conditions, add the compound B and imidazole described in step S1, use DMF and DCM as solvents, then dropwise add tert-butyldimethylsilyl trifluoromethanesulfonate at -5-0°C, react at 0-5°C, monitor the reaction by TLC, quench, extract the organic phase, dry, and purify to obtain compound C; S3, under gas protection conditions, add compound C described in step S2, DCM and diisopropylethylamine, then add triphosgene dropwise at -5-0°C, use DCM as solvent, react at 20-25°C, monitor the reaction by TLC, pour into water to quench, combine the aqueous phase and the organic phase, dry and purify to obtain the novel β-lactamase inhibitor intermediate; The novel β-lactamase inhibitor intermediate is 2. The method for synthesizing the novel β-lactamase inhibitor intermediate according to claim 1, It is characterized in that The compound A is 3. The method for synthesizing the novel β-lactamase inhibitor intermediate according to claim 1, It is characterized in that The molar ratio of compound A to hydrochloric acid in step S1 is 1:3-8.

4. The method for synthesizing the novel β-lactamase inhibitor intermediate according to claim 3, It is characterized in that The volume ratio of the hydrochloric acid-ethyl acetate solution to the ethyl acetate is 3-10:

1.

5. The method for synthesizing the novel β-lactamase inhibitor intermediate according to claim 1, It is characterized in that The equivalent ratio of the compound 2, imidazole and tert-butyldimethylsilyl trifluoromethanesulfonate described in step S2 is 1:3-6:1-3.

6. The method for synthesizing the novel β-lactamase inhibitor intermediate according to claim 1, It is characterized in that The equivalent ratio of the compound propane, diisopropylethylamine and triphosgene described in step S3 is 1:3-5:0.3-0.

4.

7. The method for synthesizing the novel β-lactamase inhibitor intermediate according to claim 1, It is characterized in that The reaction was monitored by TLC in step S2, and the TLC eluents were DCM and methanol, and the volume ratio of DCM to methanol was 15-20:

1.

8. The method for synthesizing the novel β-lactamase inhibitor intermediate according to claim 1, It is characterized in that The reaction is monitored by TLC in step S3, and the TLC eluent is petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 0.5-2:

1.

9. The method for synthesizing the novel β-lactamase inhibitor intermediate according to claim 1, It is characterized in that The quenching method in step S2 is to pour the reaction into a sodium bicarbonate solution, separate the liquids, wash with saturated brine, extract the organic phase, and dry it.

10. The method for synthesizing the novel β-lactamase inhibitor intermediate according to claim 9, It is characterized in that The mass concentration of the sodium bicarbonate solution is 10-15%.